| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CR1 |
| Uniprot No | P17927 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-234aa |
| 氨基酸序列 | GQCNAPEWLPFARPTNLTDEFEFPIGTYLNYECRPGYSGRPFSIICLKNSVWTGAKDRCRRKSCRNPPDPVNGMVHVIKGIQFGSQIKYSCTKGYRLIGSSSATCIISGDTVIWDNETPICDRIPCGLPPTITNGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCII |
| 预测分子量 | 48.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CR1重组蛋白的示例参考文献(内容为虚构示例，仅作格式参考)：
1. **标题**: *CR1 recombinant protein inhibits complement activation in a murine sepsis model*
**作者**: Smith AB, et al.
**摘要**: 研究证明重组CR1蛋白通过抑制C3转化酶活性，显著降低脓毒症小鼠模型的全身炎症反应，提高生存率。
2. **标题**: *Structural and functional characterization of human CR1 domains for malaria rosetting blockade*
**作者**: Chen L, et al.
**摘要**: 解析CR1重组蛋白的LHR结构域与疟原虫感染红细胞的相互作用机制，为开发抗疟疾药物提供结构基础。
3. **标题**: *CR1-Fc fusion protein reduces autoimmune hemolysis in vitro*
**作者**: Gupta R, et al.
**摘要**: 构建CR1与IgG Fc的融合蛋白，证实其通过增强补体调控功能，有效抑制自身免疫性溶血模型中的红细胞破坏。
注：以上文献为模拟示例，实际研究中请通过PubMed等数据库检索真实文献。
CR1 (Complement Receptor 1), also known as CD35. is a transmembrane glycoprotein that plays a critical role in regulating the complement system, a key component of innate immunity. Expressed primarily on erythrocytes, leukocytes, and glomerular podocytes, CR1 acts as a receptor for complement components C3b and C4b, facilitating the clearance of immune complexes and opsonized pathogens. It also inhibits complement activation by serving as a cofactor for the proteolytic degradation of C3b and C4b, thereby preventing excessive inflammation and tissue damage. Dysregulation of CR1 has been implicated in autoimmune diseases, infections, and age-related disorders.
Recombinant CR1 (rCR1) is engineered through genetic modification, typically using mammalian or insect cell expression systems to ensure proper post-translational modifications. The protein’s extracellular region, containing multiple complement control protein (CCP) domains, is often the focus of recombinant production. rCR1 retains the functional properties of native CR1. including complement inhibition and immune complex binding, making it a promising therapeutic candidate. For instance, soluble CR1 analogs like sCR1 (TP10) have been studied in preclinical and clinical trials for conditions such as ischemia-reperfusion injury, sepsis, and autoimmune disorders. Its ability to modulate both classical and alternative complement pathways highlights broad therapeutic potential.
Research on rCR1 also extends to biomarker development and diagnostic tools, given its role in immune regulation. Challenges remain in optimizing pharmacokinetics and minimizing immunogenicity, but advances in protein engineering continue to refine its clinical applicability. Overall, CR1 recombinant protein represents a bridge between understanding complement biology and developing targeted therapies for inflammatory and immune-mediated diseases.
×
